Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer.

Johnstone CN, Pattison AD, Gorringe KL, Harrison PF, Powell DR, Lock P, Baloyan D, Ernst M, Stewart AG, Beilharz TH, Anderson RL.

Dis Model Mech. 2018 May 29;11(5). pii: dmm032250. doi: 10.1242/dmm.032250.

2.

Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Roberts DD, Kaur S, Isenberg JS.

Antioxid Redox Signal. 2017 Oct 20;27(12):874-911. doi: 10.1089/ars.2017.7140. Epub 2017 Sep 8.

3.

The Long Noncoding RNA MALAT-1 Is Highly Expressed in Ovarian Cancer and Induces Cell Growth and Migration.

Zhou Y, Xu X, Lv H, Wen Q, Li J, Tan L, Li J, Sheng X.

PLoS One. 2016 May 26;11(5):e0155250. doi: 10.1371/journal.pone.0155250. eCollection 2016.

4.

Metalloproteinase-dependent and -independent processes contribute to inhibition of breast cancer cell migration, angiogenesis and liver metastasis by a disintegrin and metalloproteinase with thrombospondin motifs-15.

Kelwick R, Wagstaff L, Decock J, Roghi C, Cooley LS, Robinson SD, Arnold H, Gavrilović J, Jaworski DM, Yamamoto K, Nagase H, Seubert B, Krüger A, Edwards DR.

Int J Cancer. 2015 Feb 15;136(4):E14-26. doi: 10.1002/ijc.29129. Epub 2014 Aug 18.

5.

The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.

Hollern DP, Honeysett J, Cardiff RD, Andrechek ER.

Mol Cell Biol. 2014 Sep;34(17):3229-43. doi: 10.1128/MCB.00737-14. Epub 2014 Jun 16.

6.

The ADAMTS1 protease gene is required for mammary tumor growth and metastasis.

Ricciardelli C, Frewin KM, Tan Ide A, Williams ED, Opeskin K, Pritchard MA, Ingman WV, Russell DL.

Am J Pathol. 2011 Dec;179(6):3075-85. doi: 10.1016/j.ajpath.2011.08.021. Epub 2011 Oct 12.

7.

Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1.

Lee YJ, Koch M, Karl D, Torres-Collado AX, Fernando NT, Rothrock C, Kuruppu D, Ryeom S, Iruela-Arispe ML, Yoon SS.

Cancer Res. 2010 Feb 1;70(3):948-56. doi: 10.1158/0008-5472.CAN-09-3094. Epub 2010 Jan 26.

8.

A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.

Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD, Yokota J.

Genes Chromosomes Cancer. 2010 Apr;49(4):342-52. doi: 10.1002/gcc.20746.

9.

Aberrant methylation of ADAMTS1 in non-small cell lung cancer.

Choi JE, Kim DS, Kim EJ, Chae MH, Cha SI, Kim CH, Jheon S, Jung TH, Park JY.

Cancer Genet Cytogenet. 2008 Dec;187(2):80-4. doi: 10.1016/j.cancergencyto.2008.08.001.

PMID:
19027488
10.

Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC).

Rocks N, Paulissen G, Quesada Calvo F, Polette M, Gueders M, Munaut C, Foidart JM, Noel A, Birembaut P, Cataldo D.

Br J Cancer. 2006 Mar 13;94(5):724-30.

11.
12.

The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential.

Kuno K, Bannai K, Hakozaki M, Matsushima K, Hirose K.

Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33.

PMID:
15194513

Supplemental Content

Loading ...
Support Center